Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493): A first-in-human clinical experience of a folate receptor-targeted chemotherapeutic agent dosed once daily on days 1, 2, 3, and 4 of a 21-day cycle.

(2017) P. P. Peethambaram et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ovarian cancer: genomic analysis

(2013) W. Wei et al.   ANNALS OF ONCOLOGY

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

(2013) Kathryn P. Pennington et al.   CLINICAL CANCER RESEARCH

Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid–poly(ethylene glycol)–chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy

(2013) Tony Shing Chau Li et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer

(2013) Deborah K. Armstrong et al.   GYNECOLOGIC ONCOLOGY

Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper

(2013) Thomas J. Herzog et al.   GYNECOLOGIC ONCOLOGY

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

(2013) R. Wendel Naumann et al.   JOURNAL OF CLINICAL ONCOLOGY

177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy

(2013) Josefine Reber et al.   MOLECULAR CANCER THERAPEUTICS

Precursors and pathogenesis of ovarian carcinoma

(2013) D. Lim et al.   PATHOLOGY

Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro

(2012) B. A. Kamen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors

(2012) Patricia M. LoRusso et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer

(2012) Nicoletta Colombo et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer

(2012) Lana E Kandalaft et al.   Journal of Translational Medicine

Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome

(2012) Michelle K. Y. Siu et al.   PLoS One

Folate-decorated nanogels for targeted therapy of ovarian cancer

(2011) Natalia V. Nukolova et al.   BIOMATERIALS

Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer

(2011) R. Wendel Naumann et al.   DRUGS

In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin)

(2011) Pradeep K. Naik et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response

(2011) Yu-Li Chen et al.   Molecular Oncology

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Farletuzumab in epithelial ovarian carcinoma

(2010) Whitney A Spannuth et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Surveillance for the detection of recurrent ovarian cancer: Survival impact or lead-time bias?

(2010) Edward J. Tanner et al.   GYNECOLOGIC ONCOLOGY

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

(2010) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

(2010) Gordon JS Rustin et al.   LANCET

Making the best of PARP inhibitors in ovarian cancer

(2010) Susana Banerjee et al.   Nature Reviews Clinical Oncology

Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group

(2009) David S. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer

(2008) Gabriella Ferrandina et al.   JOURNAL OF CLINICAL ONCOLOGY